Barnett et al. explore the role of blood-based tumor mutation burden in predicting outcomes to immune checkpoint inhibitors in patients with advanced breast or prostate cancers. They find immune checkpoint inhibitors were not offered based on blood-based tumor mutation burden, and this did not predict response.
- Reagan M. Barnett
- Albert Jang
- Pedro Barata
